Dr. Anderson on Updated KarMMa Data With Ide-Cel in Multiple Myeloma


Larry Anderson, MD, PhD, discusses outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial.

Larry Anderson, MD, PhD, associate professor in the Department of Internal Medicine of the Division of Hematology/Oncology, at Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center, discusses outcomes with idecabtagene vicleucel (ide-cel, Abecma) in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial (NCT03361748).

The updated results from the study, presented at the 2021 International Myeloma Workshop, showed that ide-cel yielded a median overall survival (OS) of 24.8 months in heavily pretreated patients with triple-class exposed relapsed/refractory multiple myeloma, according to Anderson. Overall survival was similar for those who had received 3 or more prior lines of therapy, Anderson explains. Additionally, the median OS was more than 20 months for patients with extramedullary and triple-class refractory disease.

The CAR T-cell therapy elicited an overall response rate (ORR) of 73% and resulted in a median progression-free survival (PFS) of 8.6 months, Anderson explains. Notably, in the subset of patients who received the highest dose of CAR T cells, the ORR was even higher, at 81%, with a complete response (CR)rate of 39%. In this subset, the median PFS was 12.2 months, Anderson says.

Notably, responses to ide-cel were durable, with a median duration of response of 10.9 months among all treated patients. The durability increased with depth of response, to 21.5 months of remission for those who achieved a CR and 41% of these patients were still in remission 2 years later, Anderson concludes. 

Related Videos
D. Ross Camidge, MD, PhD
Steven Park, MD
Stephen V. Liu, MD
Ajai Chari, MD,
Tycel Phillips, MD, MPH
Terufumi Kato, MD
Sanam Loghavi, MD
Bhavana Pothuri, MD
Loretta J. Nastoupil, MD
Tycel Phillips, MD, MPH
Related Content